OncoMatch/Clinical Trials/NCT05404906
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Is NCT05404906 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Azacitidine and Venetoclax for acute myeloid leukemia (aml) in remission.
Treatment: Azacitidine · Venetoclax — This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Disease stage
Required: Stage FIRST REMISSION
are in their first remission
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Must have received: remission induction therapy
Patients who have received remission induction therapy
Must have received: cytarabine-based consolidation (cytarabine)
3-4 HiDAC or medium-dose cytarabine-based consolidation
Lab requirements
Kidney function
Creatinine Clearance Rate > or = 60 ml/min
Liver function
Serum total bilirubin <= 3 x ULN; AST and ALT <= 3 x ULN
Cardiac function
Left ventricular ejection fraction > or = 50% determined by ultrasound
Adequate organ function as follows: Serum total bilirubin <= 3 x ULN; AST and ALT <= 3 x ULN; Ccr (Creatinine Clearance Rate) > or = 60 ml/min; Left ventricular ejection fraction > or = 50% determined by ultrasound.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05404906 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received remission induction therapy and cytarabine-based consolidation.
What disease stage is eligible?
Stage FIRST REMISSION is required.
Is there an age limit?
Yes. Patients must be 64 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages